Bedfordshire and Luton Joint Prescribing Committee
Ref: JPC Bulletin 295 (March 2021)
Bulletin Date: 02/07/21
Review Date: March 2024
Iontonphoresis machine for hyperhidrosis – BLMK CCG Commissioning Statement
Iontophoresis :- Interim BLMK CCG Commissioning Statement:
The current Hyperhidrosis Statement, approved by the Priorities Forum (PF) states that a patient should only receive Botulinum Toxin for the treatment of axillary or palmar/plantar hyperhidrosis if they have a Hyperhidrosis Disease Severity Score (HDSS) score of 4 and all self-management (including iontophoresis) has been tried but has not been successful.
The PF guidance states that patients are expected to self-manage their hyperhidrosis and purchase their own machine for home treatment.
Local BLMK CCG Decision:-
As the purchase cost of an iontophoresis machine may be prohibitive for some patients, thus restricting access to the rest of the treatment pathway , BLMK CCG have agreed that patients are not required to have tried iontophoresis prior to being able to have access to Botulinum toxin for the treatment of axillary or palmar/plantar hyperhidrosis.
This position will be reviewed in the event of any updates to the Priority Forum statement and/or if a commissioned service offering Iontophoresis is launched,